Otorhinolaryngologic Neoplasms: Clinical Trials

1,463 trials for Otorhinolaryngologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

453 completed, 377 unknown, 281 recruiting, 117 active not recruiting. 567 Phase 2, 274 Not applicable, 211 Phase 3, 190 Phase 1, 19 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2567Completed 172, Unknown 146, Recruiting 99, Active not recruiting 48, Not yet recruiting 43, Terminated 42, Withdrawn 13, Suspended 3, Enrolling by invitation 1
Not applicable274Completed 95, Unknown 66, Recruiting 51, Withdrawn 18, Terminated 16, Active not recruiting 14, Not yet recruiting 13, Enrolling by invitation 1
Phase 3211Recruiting 59, Unknown 56, Completed 40, Active not recruiting 28, Not yet recruiting 15, Terminated 12, Withdrawn 1
Phase 1190Completed 81, Unknown 32, Recruiting 26, Terminated 18, Active not recruiting 14, Not yet recruiting 12, Withdrawn 6, Suspended 1
Early Phase 119Terminated 5, Completed 4, Unknown 4, Not yet recruiting 3, Recruiting 3
Phase 412Unknown 4, Completed 3, Recruiting 2, Withdrawn 2, Active not recruiting 1

Follow Otorhinolaryngologic Neoplasms: new trials by email Literature Review of Otorhinolaryngologic Neoplasms trials Research Report on Otorhinolaryngologic Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma
Chemotherapy, Computed Tomography, Endoscopic Procedure - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Not applicableNot yet recruitingCity of Hope Medical Center302027-06-222026-11-09
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer
Phase 1Not yet recruitingM.D. Anderson Cancer Center482027-03-012026-09-21
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma
Phase 1RecruitingNational Cancer Institute (NCI)392027-02-132026-10-29
Role of ChatGPT in Vestibular Schwannoma Management
Use of chatGPT for 1 week - Vestibular Schwannoma
Not applicableWithdrawnUniversity of Southern California2027-01-012026-01-13
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Phase 1Not yet recruitingMemorial Sloan Kettering Cancer Center602026-12-012026-11-03
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Phase 2Not yet recruitingSun Yat-sen University2982026-12-012026-10-27
Selumetinib for NF2-Related Schwannomatosis
Selumetinib - Neurofibromatosis Type 2, NF2
Phase 2Not yet recruitingBeijing Tiantan Hospital202026-12-012026-10-28
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Phase 1 / Phase 2Not yet recruitingWashington University School of Medicine452026-11-302026-11-03
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1202026-11-192026-11-16
Study of MC001 in Patients With Advanced Solid Tumours
MC001 - Pancreatic Ductal Adenocarcinoma (PDAC), Nasopharyngeal Carcinoma
Phase 1Not yet recruitingNational University Hospital, Singapore802026-11-162026-11-10
A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma
SYS6010 combined with Enlonstobart, Tislelizumab combined with chemotherapy - Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.4242026-11-062026-11-09
Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
Assessment of EBV-related blood biomarkers and nasopharyngeal endoscopic scores - Nasopharyngeal Carcinoma (NPC)
Not yet recruitingZhongshan People's Hospital, Guangdong, China15002026-11-012026-11-05
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab - Nasopharyngeal Carcinoma (NPC)
Phase 2Not yet recruitingSun Yat-sen University302026-11-012026-10-29
Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer
Biospecimen Collection, Carboplatin, Chemotherapy - Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Phase 2Not yet recruitingMayo Clinic502026-11-012026-11-09
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer
Phase 2RecruitingUniversity of Maryland, Baltimore1322026-10-192026-11-06
Off-line Adaptive Proton Therapy
Off-line Adaptive Proton Therapy (o-APT) Workflow Evaluation - Oropharyngeal Carcinoma
Not yet recruitingUniversity Medical Center Groningen1002026-10-012026-10-08
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis
Phase 2Not yet recruitingSun Yat-sen University1382026-10-012026-09-17
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)
Phase 1RecruitingMetaclipse Therapeutics Corporation302026-10-012026-10-27
Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral Surgery
Intraoperative soft palate suspension using the double-strap method., Intraoperative soft palate suspension using the full-wrap method. - Adenoid Hypertrophy, Tonsillar Hypertrophy
Not applicableNot yet recruitingSun Yat-sen University1382026-09-302026-07-10
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC)
Phase 3RecruitingSun Yat-sen University2042026-09-292026-10-15

Showing 20 of 1463. Sign in to see all of them.

Narrower conditions

Nasopharyngeal Carcinoma (651)  ·  Oropharyngeal Neoplasms (368)  ·  Laryngeal Neoplasms (257)  ·  Head and Neck Neoplasms (226)  ·  Nasopharyngeal Neoplasms (224)  ·  Mouth Neoplasms (162)  ·  Squamous Cell Carcinoma of Head and Neck (151)  ·  Hypopharyngeal Neoplasms (147)  ·  Neuroma, Acoustic (98)  ·  Uterine Cervical Neoplasms (56)  ·  Carcinoma, Non-Small-Cell Lung (53)  ·  Carcinoma (50)  ·  Esophageal Neoplasms (47)  ·  Neurofibromatosis 2 (47)  ·  Neoplasms (46)

Broader conditions

Otorhinolaryngologic Diseases (1454)  ·  Neoplasms by Site (1438)  ·  Neoplasms (1417)  ·  Stomatognathic Diseases (1221)  ·  Pharyngeal Diseases (1213)  ·  Pharyngeal Neoplasms (1179)  ·  Head and Neck Neoplasms (1116)  ·  Neoplasms by Histologic Type (977)  ·  Neoplasms, Glandular and Epithelial (863)  ·  Nasopharyngeal Diseases (822)  ·  Carcinoma (795)  ·  Nasopharyngeal Neoplasms (603)  ·  Respiratory Tract Diseases (326)  ·  Respiratory Tract Neoplasms (316)

Interventions

Cisplatin (241)  ·  Radiotherapy, Intensity-Modulated (110)  ·  Gemcitabine (96)  ·  Radiotherapy (83)  ·  Docetaxel (68)  ·  Fluorouracil (59)  ·  toripalimab (52)  ·  Capecitabine (45)  ·  Carboplatin (39)  ·  Drug Therapy (39)  ·  pembrolizumab (38)  ·  Magnetic Resonance Spectroscopy (34)  ·  Radiation (34)  ·  Cetuximab (33)  ·  camrelizumab (31)

Sponsors

Sun Yat-sen University (215)  ·  National Cancer Institute (NCI) (51)  ·  M.D. Anderson Cancer Center (36)  ·  Fudan University (35)  ·  Zhejiang Cancer Hospital (24)  ·  Fujian Cancer Hospital (18)  ·  Eye & ENT Hospital of Fudan University (16)  ·  Memorial Sloan Kettering Cancer Center (16)  ·  Mayo Clinic (15)  ·  Jiangxi Provincial Cancer Hospital (14)  ·  National University Hospital, Singapore (14)  ·  Ming-Yuan Chen (10)  ·  National Taiwan University Hospital (10)  ·  UNC Lineberger Comprehensive Cancer Center (10)  ·  Chinese University of Hong Kong (9)

Countries

China (574)  ·  United States (440)  ·  France (77)  ·  Taiwan (45)  ·  Canada (44)  ·  Singapore (42)  ·  United Kingdom (32)  ·  Hong Kong (26)  ·  Italy (26)  ·  Germany (23)  ·  Netherlands (19)  ·  Spain (19)  ·  Denmark (16)  ·  Australia (14)  ·  South Korea (13)

Top investigators

Jun Ma, M.D. (14)  ·  Ming-Yuan Chen, MD,PhD (11)  ·  Ming-Yuan Chen, MD, PhD (9)  ·  Chaosu Hu, MD (7)  ·  Jiade J Lu, MD (6)  ·  Fang-Yun Xie, M.D. (5)  ·  Ming-yuan Chen, MD, PhD (5)  ·  Yun-fei Xia, MD (5)  ·  Charalampos Floudas, M.D. (4)  ·  Chong Zhao, M.D (4)  ·  Jian Guan, Ph.D. (4)  ·  Li Zhang, MD (4)  ·  Nancy Lee, MD (4)  ·  Wei Jiang, Ph.D. (4)  ·  Xiaozhong Chen (4)

Results publications

PMID 31150573, PMID 30207593, PMID 27686945, PMID 28837405, PMID 29584545, PMID 34341578, PMID 30213452, PMID 31178151, PMID 33492986, PMID 35240053, PMID 35997729, PMID 36746459, PMID 38507662, PMID 39970442, PMID 17917842, PMID 19564532, PMID 19574236, PMID 19645909, PMID 22027076, PMID 22154591, PMID 27567279, PMID 27567280, PMID 30620929, PMID 31536129, PMID 32017652, PMID 34111416, PMID 34174189, PMID 34990291, PMID 35355438, PMID 35709465, PMID 37207654, PMID 37409613, PMID 37537541, PMID 37580352, PMID 37801967, PMID 38520712, PMID 39438442, PMID 40692081, PMID 40890288, PMID 41791006, PMID 41813900, PMID 42032732, PMID 42580817, PMID 10449559, PMID 10623691, PMID 10640954, PMID 10811668, PMID 10924966, PMID 11127145, PMID 11212235

NIH funding

U10CA180868 (8), P30CA138292 (6), U10CA180820 (6), 2017 (3), 2018 (3), 2019 (3), P30CA006973 (3), P30CA012197 (3), U10CA180821 (3), 2014 (2), 2015 (2), 2023 (2), P30CA014520 (2), P30CA015083 (2), P30CA016056 (2)